Business
Vogenx Raises $81M in IPO to Tackle a Little-Known Side Effect of Weight-Loss Surgery
The Raleigh biotech priced its Nasdaq debut at $13 a share to fund mizagliflozin, an oral drug aimed at the dangerous blood-sugar crashes some patients face after bariatric surgery.